Aprea Therapeutics, Inc(NASDAQ:APRE) 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical d...
Website: http://www.aprea.com
Founded: 2006
IPO Price: $15 (Oct 03, 2019)
Full Time Employees: 13
CEO: Christian S. Schade
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.80
H 1.85
L 1.67
C 1.70
V 89,919
10EMA 1.70
20EMA 1.70
60EMA 1.70
120EMA 1.70
250EMA 1.70